Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Sets Out Plan to Ease Export Ban for Plasma Fraction Products
The Ministry of Health, Labor and Welfare (MHLW) plans to ease a long-standing export ban on blood plasma fraction products to allow such exports, excluding immunoglobulin and albumin preparations, in response to a call from a ministry task force on…
To read the full story
Related Article
- Turning Point for Blood Products? Discussions on Basic Policy on Blood Law Moving Ahead
February 20, 2018
- MHLW Approves Proposed Reforms to Allow the Export of Plasma Fraction Products
December 19, 2017
- MHLW Looks to Lift Ban on Exports of Plasma Fraction Products by FY2020
December 1, 2017
- MHLW Panel Recommends Moving Ahead with Discussions toward Easing Regulations on Export of Blood Products
June 16, 2017
- MHLW Panel Initiates Discussions on Whether to Lift Ban on Export of Blood Products
March 17, 2017
REGULATORY
- MHLW Revises Biological Raw Material Rules, Clarifies Donor Testing Flexibility
April 2, 2026
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Updates Q&A on Use of Registry Data in Drug Applications
April 1, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…